{"filings":[{"id":747676,"accession_number":"0001730430-26-000029","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2026-05-29T20:35:27+00:00","items":["5.07"],"status":"ready","headline":"Kiniksa shareholders re-elect all three Class II directors and approve all eight proposals at 2026 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stephen R. Biggar re-elected with 37.5M for, 12.0M against; G. Bradley Cole and Barry D. Quart each received ~48.3M for.","PricewaterhouseCoopers LLP approved as both UK statutory auditor and US independent auditor with overwhelming votes.","Advisory vote on named executive officer compensation passed with 48.1M for and 1.3M against.","All eight proposals, including director elections, auditor appointments, and remuneration reports, were duly passed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":669556,"accession_number":"0001730430-26-000025","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2026-05-26T20:55:02+00:00","items":["1.01","9.01"],"status":"ready","headline":"Kiniksa caps Baker Bros. voting power at 49.9% by waiving conversion rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Baker Bros. entities hold 12.78M A1 and 16.06M B1 shares; they waive conversion into A/B shares if ownership exceeds 49.9% voting rights.","Waiver is irrevocable and unconditional; amendment requires at least 75% shareholder approval.","Deed prohibits circumvention; any conversion attempt violating the cap is void ab initio.","Other shareholder rights (voting, dividends, capital return) remain unaffected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95055,"accession_number":"0001730430-26-000021","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2026-05-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kiniksa CSO Eben Tessari resigns, signs consulting deal at $450/hr","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Eben Tessari resigned as Chief Strategy Officer effective May 15, 2026, to take another life-sciences executive role.","Decision not due to any disagreement with the company on operations, policies, or practices.","Will serve as consultant and special advisor to Science and Research Committee for up to 20 hours/month at $450/hour.","Consulting agreement runs from May 15, 2026 to May 15, 2027, renewable by mutual agreement.","Company reimburses reasonable pre-approved travel and out-of-pocket expenses for consulting services."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95054,"accession_number":"0001730430-26-000017","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Reports Q1 2026 ARCALYST Revenue of $214.3M, Raises 2026 Guidance to $930-$945M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST Q1 2026 net product revenue $214.3 million, representing 56% year-over-year growth.","2026 ARCALYST net product revenue guidance raised to $930-$945 million from prior $900-$920 million.","Cash and short-term investments $468.1 million, no debt; net income $22.6 million in Q1 2026.","KPL-387 Phase 2 data in recurrent pericarditis expected in 2H 2026; Phase 3 trial by year-end.","Over 4,550 prescribers for ARCALYST in recurrent pericarditis; average therapy duration approaching 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":214266000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107855,"accession_number":"0001730430-26-000014","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa reports Q4/FY 2025 net income; ARCALYST revenue up 62% to $677.6M; guides 2026 $900-920M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net product revenue $202.1M Q4, $677.6M FY 2025 (+62% YoY); gross-to-net improved to 8.4%.","Net income $14.2M Q4, $59.0M FY 2025 vs net loss of $8.9M/$43.2M in prior-year periods.","Cash, cash equivalents & short-term investments $414.1M, no debt, up from $243.6M.","2026 ARCALYST revenue guidance $900-$920M; company expects positive annual cash flow from operations.","KPL-387 Phase 2/3 recurrent pericarditis data expected 2H 2026; KPL-1161 Phase 1 planned by end of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":677564000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107854,"accession_number":"0001730430-26-000010","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kiniksa appoints Ross Moat as COO and Eben Tessari as Chief Strategy Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ross Moat promoted to COO effective Jan 10, 2026; will oversee commercial and functional operations.","Eben Tessari appointed Chief Strategy Officer effective Jan 10, 2026; adds AI initiatives to strategy and BD.","No changes to compensation for either executive in connection with the appointments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107853,"accession_number":"0001730430-26-000005","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa 2025 ARCALYST revenue $677.5M (+62% YoY), guides 2026 to $900-920M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARCALYST net product revenue $677.5M in 2025, up ~62% YoY from $417.0M in 2024.","2026 ARCALYST revenue guidance $900-920M; gross-to-net improved to 8.4% from 9.8%.","Cash and short-term investments $414.1M, no debt; increased $170.4M in 2025.","KPL-387 Phase 2 dose-focusing data expected 2H 2026; KPL-1161 Phase 1 by year-end 2026.","~18% of 14,000 multiple-recurrence patients on ARCALYST; >4,150 prescribers since launch."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":124252,"accession_number":"0001104659-25-102834","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q3 ARCALYST revenue $180.9M (+61% YoY); raises 2025 guidance to $670-675M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $18.4M (vs loss $12.7M); cash $352.1M, no debt.","ARCALYST net product revenue $180.9M, up 61% YoY; total revenue $180.9M.","2025 revenue guidance raised to $670-675M from prior $625-640M.","KPL-387 granted Orphan Drug Designation; Phase 2/3 data H2 2026.","Prescribers >3,825; average therapy duration ~32 months."],"consensus_eps_estimate":null,"consensus_eps_actual":0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":475437000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140932,"accession_number":"0001104659-25-086689","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-09-03T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kiniksa posts September 2025 investor presentation, no material new information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Investor presentation posted on investors.kiniksa.com on September 3, 2025.","Presentation expected to be used in meetings with investors and analysts.","No financial results, guidance, or specific corporate events announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140931,"accession_number":"0001104659-25-071413","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q2 ARCALYST revenue $156.8M (+52% YoY); raises 2025 guidance to $625-640M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net product revenue $156.8M in Q2 2025, up 52% from $103.4M in Q2 2024 (excl. $5.2M license revenue).","2025 ARCALYST net revenue guidance raised to $625-640M from prior $590-605M, reflecting continued commercial execution.","Net income of $17.8M in Q2 2025 vs net loss of $3.9M in Q2 2024; cash and investments $307.8M, no debt.","KPL-387 Phase 2/3 trial in recurrent pericarditis recruiting; Phase 2 data expected in 2H 2026.","Approximately 15% of target 14,000 multiple-recurrence pericarditis patients currently on ARCALYST."],"consensus_eps_estimate":null,"consensus_eps_actual":0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":294582000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158691,"accession_number":"0001104659-25-056665","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Kiniksa details Phase 2/3 trial design for KPL-387 in recurrent pericarditis; initiation mid-2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2/3 trial: dose-focusing portion enrolls up to ~80 patients; pivotal portion up to ~85.","Primary endpoint: time to treatment response at Week 24 (Phase 2) and time to first recurrence (Phase 3).","Phase 1 single ascending dose data support monthly subcutaneous dosing with liquid formulation.","Phase 2 data expected in second half of 2026.","Corporate presentation at Jefferies 2025 Global Healthcare Conference at 12:50 pm ET on June 5."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158690,"accession_number":"0001104659-25-055990","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kiniksa shareholders elect all director nominees and approve all 13 proposals at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected; Stephen R. Biggar received 15.3M against votes, Felix J. Baker 12.3M against.","Say-on-pay (Prop 10) passed with 49.1M for, 550.7K against.","Authority to allot shares up to ~35% of share capital (Prop 11) passed: 41.2M for, 11.2M against.","Disapplication of pre-emption rights (Prop 12) passed: 40.7M for, 11.7M against.","Preference share redemption to create distributable reserves (Prop 13) passed with 52.4M for, 23.2K against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158689,"accession_number":"0001104659-25-040641","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q1 2025 ARCALYST revenue $137.8M (+75% YoY); guides FY 2025 to $590-605M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net product revenue $137.8M in Q1 2025, up 75% YoY; net income $8.5M vs loss of $17.7M in Q1 2024.","Full-year 2025 ARCALYST net product revenue guidance raised to $590-605M from prior $560-580M.","KPL-387 Phase 2/3 trial in recurrent pericarditis on track to initiate mid-2025; Phase 2 data expected 2H 2026.","Cash and investments $268.3M, no debt; current operating plan expected cash flow positive annually.","Tariff impact on ARCALYST gross margin expected immaterial; manufacturing transfer to Samsung Biologics ongoing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.11,"consensus_revenue_estimate":null,"consensus_revenue_actual":137785000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158688,"accession_number":"0001104659-25-038041","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Kiniksa approves KPL-387 LTIP for execs, grants PSUs and options tied to BLA submission and FDA approval","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved KPL-387 Long-Term Incentive Plan for executive officers, linked to BLA submission (Milestone 1) and FDA approval (Milestone 2) for recurrent pericarditis treatment.","CEO Sanj Patel granted 16,312 PSUs and 26,142 options; CFO Mark Ragosa granted 9,309 PSUs and 14,918 options.","Awards include cash, PSUs, and options, with earnout percentages (100%, 75%, 50%, 0%) based on milestone achievement dates.","If a change in control occurs, unvested awards may accelerate under specified conditions, including termination without cause or resignation for good reason.","The plan covers five named executive officers; cash award amounts are based on base salary at milestone achievement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177080,"accession_number":"0001104659-25-016725","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["1.02","2.02","2.05","9.01"],"status":"ready","headline":"Kiniksa Q4 ARCALYST rev $122.5M ($417M FY); guides 2025 $560-580M; discontinues mavrilimumab & abiprubart","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST Q4 net product revenue $122.5M; full year $417.0M (79% YoY growth).","2025 ARCALYST revenue guidance $560-580M; expects annual cash flow positive.","Terminated MedImmune license for mavrilimumab; effective May 22, 2025.","Discontinued abiprubart Phase 2b trial in Sjögren's Disease; expects $14-17M additional expenses.","Net loss Q4 $8.9M (vs net income $25.2M); full year net loss $43.2M (vs net income $14.1M)."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":423239000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177079,"accession_number":"0001104659-25-002858","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa reports 2024 ARCALYST net product revenue $416.4M (+79% YoY); guides 2025 to $560-580M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ARCALYST net product revenue: Q4 2024 $121.9M, FY 2024 $416.4M (unaudited), ~79% YoY growth.","2025 ARCALYST net product revenue guidance: $560M to $580M.","Approximately 13% of target 14,000 multiple-recurrence pericarditis patients actively on ARCALYST as of Q4 2024.","Cash, cash equivalents, and short-term investments of $243.6M as of Dec 31, 2024; expects to remain cash flow positive annually.","Over 2,850 prescribers have written ARCALYST prescriptions; average therapy duration ~27 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193855,"accession_number":"0001104659-24-112034","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q3 ARCALYST revenue $112.2M (+73% YoY); FY guidance raised to $410-420M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST Q3 net product revenue $112.2M, up 73% YoY; FY 2024 guidance raised to $410-420M from $405-415M.","Net loss narrowed to $12.7M from $13.9M; cash $223.8M, no debt.","Over 2,550 prescribers since launch; average therapy duration ~27 months.","Phase 2b trial of abiprubart in Sjögren's Disease enrolling/dosing; expects annual cash flow positivity.","Launched Life DisRPted campaign with Henrik Lundqvist and Carly Pearce."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":300703000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193854,"accession_number":"0001104659-24-106690","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Kiniksa appoints M. Cantey Boyd to Board, increasing size to 10 directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from 9 to 10; Boyd appointed as Class III director.","Boyd is a Managing Director at Baker Bros. Advisors LP, a life sciences investment firm.","She will serve on Compensation Committee; receives standard non-employee director compensation.","No material transactions between Boyd and the company; standard indemnification agreement entered."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":210192,"accession_number":"0001104659-24-081717","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q2 ARCALYST revenue $103.4M (+90% YoY); 2024 guidance raised to $405-415M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net product revenue $103.4M in Q2 2024, up 90% YoY; ~11% of target 14,000 patients on therapy.","Total revenue $108.6M (Q2 2024) vs $71.5M (Q2 2023); net loss $3.9M vs net income $15.0M YoY.","2024 ARCALYST net revenue guidance increased to $405-415M from prior $370-390M.","Cash and investments $218.8M, no debt; expects to remain cash flow positive annually.","Phase 2b trial of abiprubart in Sjögren's Disease enrolling; clinical development fully funded."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":188489000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228451,"accession_number":"0001104659-24-076282","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K12B","filed_at":"2024-06-28T23:59:59+00:00","items":["1.01","3.01","3.02","3.03","5.03","5.02","8.01","9.01"],"status":"ready","headline":"Kiniksa completes redomiciliation from Bermuda to UK, shares trade on Nasdaq under same symbol KNSA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective June 27, 2024, Kiniksa redomiciled to UK via Bermuda court-approved scheme of arrangement.","Shareholders received one-for-one exchange of shares; ~40.4M Class A, 1.8M B, 12.8M A1, 16.1M B1 ordinary shares issued.","Class A Ordinary Shares continue trading on Nasdaq under symbol KNSA as of June 28, 2024.","Same executive officers and directors continue; indemnification agreements and equity plans assumed.","Depositary receipts issued for shares not directly eligible for DTC transfer to avoid UK stamp duty."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228456,"accession_number":"0001104659-24-074763","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-06-25T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Kiniksa signs manufacturing agreement with Samsung Biologics for ARCALYST","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Wholly-owned subsidiary entered MSA and PSA with Samsung Biologics for ARCALYST (rilonacept) drug substance.","Kiniksa committed to purchase PPQ and pre-approval inspection batches; additional batches required in 2027-2031.","PSA continues until later of Dec 31, 2031 or service completion; MSA initial 10-year term with 2-year auto-renewals.","Agreement includes customary indemnification, IP protection, limitation of liability, and confidentiality provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228455,"accession_number":"0001104659-24-071787","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Kiniksa gets Bermuda court sanction for redomiciliation to UK, effective ~June 27","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Bermuda Supreme Court sanctioned the scheme of arrangement on June 14, 2024.","Shareholders approved the redomiciliation at a court-ordered meeting on June 5, 2024.","Redomiciliation from Bermuda to UK expected to take effect on or around June 27, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228454,"accession_number":"0001104659-24-068694","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Kiniksa shareholders approve redomiciliation scheme; court sanction hearing set for June 14","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Scheme of arrangement approved by 61,460,949 votes for, 501,355 against, 274,060 abstained.","Supreme Court of Bermuda sanction hearing expected on or around June 14, 2024 at 9:30 a.m. AST.","At annual meeting, directors Felix J. Baker, Tracey L. McCain, Kimberly J. Popovits re-elected; auditor PwC ratified; say-on-pay passed.","Redomiciliation meeting was held immediately after annual meeting per Bermuda court order dated April 19, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.15,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":228453,"accession_number":"0001104659-24-050335","cik":1730430,"company_name":"Kiniksa Pharmaceuticals International, plc","ticker":"KNSA","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Kiniksa Q1 ARCALYST revenue $78.9M (+85% YoY); raises 2024 guidance to $370-390M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ARCALYST net product revenue $78.9M in Q1 2024, up 85% YoY; total revenue $79.9M vs $48.3M in Q1 2023.","Net loss $17.7M vs $12.3M loss in Q1 2023; cash and investments $213.6M, no debt outstanding.","Raises 2024 ARCALYST net product revenue guidance to $370-390M from prior $360-380M.","Plans to initiate abiprubart Phase 2b trial in Sjögren's Disease in second half of 2024.","About 2,000 prescribers have written ARCALYST since launch; average therapy duration ~23 months."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":79858000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3952305896.3479934,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}